Actively Recruiting

Phase 2
Age: 18Years +
All Genders
NCT05129748

Efficacy of Sodium Thiosulfate and Mannitol in Reducing Ototoxicity in Adult Patients Receiving Cisplatin Chemotherapy

Led by Sunnybrook Health Sciences Centre · Updated on 2023-04-14

92

Participants Needed

1

Research Sites

250 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

One common side effect of cisplatin chemotherapy is ototoxicity. The drugs sodium thiosulfate and mannitol may protect against cisplatin-induced hearing loss. Specifically, sodium thiosulfate has been found to protect the cells in the inner ear, and may therefore prevent hearing loss. Mannitol can help sodium thiosulfate enter the inner ear, and ponteially increase the effectiveness of sodium thiosulfate. This study aims to assess the efficacy of sodium thiosulfate and mannitol to reduce the hearing impairment caused by cisplatin chemotherapy.

CONDITIONS

Official Title

Efficacy of Sodium Thiosulfate and Mannitol in Reducing Ototoxicity in Adult Patients Receiving Cisplatin Chemotherapy

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients undertaking systemic cisplatin therapy as part of their cancer treatment
  • Age 218
  • Willing to provide informed consent
  • ECOG performance status 0-2
  • For females of child-bearing potential, a negative pregnancy test (beta-HCG) prior to study treatment is required
  • Patients of reproductive age must agree in writing to use effective contraception during the trial
Not Eligible

You will not qualify if you...

  • Age less than 18
  • Preexisting severe to profound sensorineural hearing loss (speech reception threshold >70dB, or word recognition score <50%) confirmed by audiogram
  • History of Meniere's disease or fluctuating hearing loss
  • Asymmetrical hearing loss with specific bone conduction threshold differences
  • Abnormal kidney function (creatinine clearance <60 ml/min)
  • Abnormal liver function tests (ALT and ALP >2.5 times upper limit without liver metastasis; >5 times with metastasis)
  • Previous hypersensitivity to sodium thiosulfate or mannitol
  • Pregnant or nursing women
  • Inability to follow the study protocol for any reason

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Sunnybrook Health Sciences Centre

Toronto, Ontario, Canada

Actively Recruiting

Loading map...

Research Team

Y

Yasmeen Aboulhawa

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

PREVENTION

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here